Kihealth, a precision diagnostics company specializing in early disease detection, announced the close of its $5 million oversubscribed seed round, marking a major milestone in its mission to transform metabolic health screening. The investment round reflects strong investor confidence in Kihealth’s first-of-its-kind diagnostic technology, which recently earned the 2025 American Diabetes Association (ADA) Innovation of the Year Award.
The newly raised capital will fund the commercial rollout of Kihealth’s laboratory-developed test that measures biomarkers of beta cell apoptosis — an early and sensitive indicator of insulin resistance and chronic metabolic diseases such as diabetes. Unlike traditional glucose-based diagnostics, Kihealth’s minimally invasive test provides clinicians with an unprecedented view into pancreatic beta cell health from a simple blood draw, enabling earlier and more accurate detection of disease progression.
Developed in collaboration with leading academic researchers, Kihealth’s proprietary platform addresses a massive $2 billion-plus diagnostics market that currently lacks direct competition. By allowing healthcare providers to detect disease earlier and track therapeutic impact through measurable biomarkers, the company’s platform has the potential to revolutionize the management of both Type 1 and Type 2 diabetes.
In Type 1 Diabetes Prevention Trials, the technology can identify high-risk individuals beyond traditional autoantibody screening, measure early therapeutic responses via beta cell apoptosis as a pharmacodynamic endpoint, and refine clinical trial design by distinguishing fast from slow progressors.
In Type 2 Diabetes and Obesity Care, the same assay can pinpoint patients with rapid beta cell decline despite normal glucose levels, monitor treatment efficacy, and improve patient stratification to ensure stronger clinical outcomes and trial reliability.
The company plans to expand its pipeline of minimally invasive diagnostic tools, leveraging its platform to uncover hidden disease processes across a broader spectrum of chronic and metabolic conditions.
KEY QUOTES:
“Our mission is to detect disease earlier and intervene smarter. This new diagnostic test represents the future of preventive medicine: giving providers the power to act before overt disease takes hold, empowering patients with clarity, and enabling pharma to deliver more targeted, effective therapies. Together, we can redefine the standard of care for obesity, diabetes, and beyond.”
Jennifer Anderson, Chief Executive Officer and Co-Founder, Kihealth Inc.
